Login / Signup

Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.

Eugenia GkaliagkousiEugenia GkaliagkousiAreti TriantafyllouBarbara NikolaidouPanagiota AnyfantiNikolaos KoletsosAnastasios VamvakisKonstantina DiplaAntonios LazaridisStella Douma
Published in: Journal of clinical hypertension (Greenwich, Conn.) (2018)
Asymmetric dimethylarginine (ADMA) is a robust marker of endothelial dysfunction in patients with essential hypertension. We investigated ADMA levels and their association with vascular damage in untreated hypertension. We enrolled consecutive patients with untreated, recently diagnosed hypertension and age-matched normotensive individuals. 24-hour blood pressure, central hemodynamics, and arterial stiffness were recorded. A total of 311 individuals were studied: 165 with essential hypertension, 50 with masked hypertension, 25 with white-coat hypertension, and 71 normotensive individuals. ADMA levels significantly correlated with aortic augmentation index (AIx75) (r = .156, P = .006), aortic pulse pressure (r = .153, P = .007) and marginally with carotid-femoral pulse wave velocity (r = .110, P = .051), as well as with diastolic office BP. In the multivariate model, aortic AIx75 and age were the only statistically significant predictors of ADMA. This is the largest study to document an independent association between ADMA and aortic AIx75 but not with other indices of arterial stiffness.
Keyphrases
  • blood pressure
  • hypertensive patients
  • heart rate
  • aortic valve
  • left ventricular
  • pulmonary artery
  • blood glucose
  • coronary artery
  • heart failure
  • type diabetes
  • high resolution
  • aortic dissection
  • insulin resistance